ST
BCRX icon

Spot Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Spot Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-19,000
Closed -$196K – 3449
2015
Q4 		$196K Hold
19,000
– – ﹤0.01% 2485
2015
Q3 		$217K Buy
+19,000
New +$254K ﹤0.01% 2644
2015
Q1 		– Sell
-11,200
Closed -$136K – 3903
2014
Q4 		$136K Buy
+11,200
New +$124K ﹤0.01% 3124

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spot Trading's BCRX Position: Q4 2016 in Review

Spot Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2016, closing a stake of 11,168 shares — an estimated $58.1K sold.

Spot Trading first reported a position in BCRX in Q4 2014 and held it in 3 quarters. The position peaked at $117K in Q4 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

  • Spot Trading reported no remaining BioCryst Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 11,168 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $58.1K.
  • Spot Trading first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 3 quarters.
  • Spot Trading's BioCryst Pharmaceuticals position peaked at $117K in Q4 2015.
  • 112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.